SYNDAX PHARMACEUTICALS, INC.Stock Unit Agreement • August 6th, 2020 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
Syndax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants Stock Units denominated in shares of its common stock, par value $0.0001 per share (this “Award”), to the Grantee named below, subject to the vesting and other conditions set forth below. Additional terms and conditions of the grant are set forth in this cover sheet and in the attachment (collectively, the “Agreement”), and in the Company’s 2015 Omnibus Incentive Plan (as amended from time to time, the “Plan”).
AMENDMENT NO. 12 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • August 6th, 2020 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 12 to Clinical Trial Agreement (the “Amendment” or “Amendment 12”) is entered into as of May 12, 2020 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
